Approaches to M&As in pharma points to each company’s philosophy
Deal or no deal
Related Posts
Phesi’s AI-driven Trial Accelerator platform contains over 100 million patients
The platform delivers digitalised patient data to improve clinical trials and development Phesi has announced that its artificial intelligence (AI)-driven Trial Accelerator platform has reached […]
Dr Rafiq Hasan – PharmaTimes
Exonate has appointed Dr Rafiq Hasan as Non-Executive Director. Exonate has announced the expansion of its Board with the appointment of Dr Rafiq Hasan as Non-Executive Director. Rafiq brings extensive […]
IRLAB’s new drug shows promise in treating apathy in Parkinson’s patients
Phase 1 trial of IRL757 demonstrates good absorption and safety profile IRLAB Therapeutics AB has announced the successful completion of the first part of its […]